Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
J Am Chem Soc. 2023 Apr 12;145(14):8176-8188. doi: 10.1021/jacs.3c01421. Epub 2023 Mar 28.
Nuclear receptor-binding SET domain-containing 2 (NSD2) plays important roles in gene regulation, largely through its ability to dimethylate lysine 36 of histone 3 (H3K36me2). Despite aberrant activity of NSD2 reported in numerous cancers, efforts to selectively inhibit the catalytic activity of this protein with small molecules have been unsuccessful to date. Here, we report the development of UNC8153, a novel NSD2-targeted degrader that potently and selectively reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 through a novel mechanism. Importantly, UNC8153-mediated reduction of H3K36me2 through the degradation of NSD2 results in the downregulation of pathological phenotypes in multiple myeloma cells including mild antiproliferative effects in MM1.S cells containing an activating point mutation and antiadhesive effects in KMS11 cells harboring the t(4;14) translocation that upregulates NSD2 expression.
核受体结合 SET 域包含蛋白 2(NSD2)在基因调控中发挥重要作用,主要通过其将组蛋白 3(H3)赖氨酸 36 二甲基化的能力(H3K36me2)。尽管在许多癌症中报道了 NSD2 的异常活性,但迄今为止,用小分子选择性抑制该蛋白的催化活性的努力尚未成功。在这里,我们报告了 UNC8153 的开发,这是一种新型的 NSD2 靶向降解剂,能够强烈和选择性地降低 NSD2 蛋白和 H3K36me2 染色质标记的细胞水平。UNC8153 含有一个简单的弹头,通过一种新的机制通过蛋白酶体依赖性降解 NSD2。重要的是,UNC8153 通过降解 NSD2 介导的 H3K36me2 的减少导致多发性骨髓瘤细胞中病理表型的下调,包括含有激活点突变的 MM1.S 细胞中的轻度抗增殖作用和上调 NSD2 表达的 KMS11 细胞中的抗粘附作用。